Logo Logo
Hilfe
Hilfe
Switch Language to English

Gottschlich, Adrian ORCID logoORCID: https://orcid.org/0000-0002-2898-4182; Grünmeier, Ruth ORCID logoORCID: https://orcid.org/0000-0002-9044-3600; Hoffmann, Gordon Victor ORCID logoORCID: https://orcid.org/0009-0007-3167-2124; Nandi, Sayantan; Kavaka, Vladyslav ORCID logoORCID: https://orcid.org/0009-0004-5837-3384; Müller, Philipp Jie; Jobst, Jakob; Öner, Arman ORCID logoORCID: https://orcid.org/0000-0003-2754-5417; Kaiser, Rainer ORCID logoORCID: https://orcid.org/0000-0003-1750-3395; Gärtig, Jan; Piseddu, Ignazio ORCID logoORCID: https://orcid.org/0000-0001-8331-9778; Frenz-Wießner, Stephanie ORCID logoORCID: https://orcid.org/0000-0001-8862-3752; Fairley, Savannah D. ORCID logoORCID: https://orcid.org/0009-0001-8310-2074; Schulz, Heiko; Igl, Veronika ORCID logoORCID: https://orcid.org/0000-0003-4618-2383; Janert, Thomas Alexander ORCID logoORCID: https://orcid.org/0009-0007-2466-7650; Di Fina, Lea; Mulkers, Maité ORCID logoORCID: https://orcid.org/0009-0003-4402-2682; Thomas, Moritz ORCID logoORCID: https://orcid.org/0000-0002-8422-2414; Briukhovetska, Daria ORCID logoORCID: https://orcid.org/0000-0002-2073-2335; Simnica, Donjetë ORCID logoORCID: https://orcid.org/0000-0003-2286-1381; Carlini, Emanuele; Tsiverioti, Christina Angeliki ORCID logoORCID: https://orcid.org/0009-0008-4055-1196; Trefny, Marcel P. ORCID logoORCID: https://orcid.org/0000-0001-6755-7899; Lorenzini, Theo ORCID logoORCID: https://orcid.org/0000-0003-3377-032X; Märkl, Florian ORCID logoORCID: https://orcid.org/0000-0003-4285-0380; Mesquita, Pedro ORCID logoORCID: https://orcid.org/0009-0007-4285-9269; Brabenec, Ruben ORCID logoORCID: https://orcid.org/0000-0002-8820-220X; Strzalkowski, Thaddäus ORCID logoORCID: https://orcid.org/0000-0002-7191-0410; Stock, Sophia ORCID logoORCID: https://orcid.org/0000-0002-5072-5013; Michaelides, Stefanos ORCID logoORCID: https://orcid.org/0000-0002-9001-0207; Hellmuth, Johannes C. ORCID logoORCID: https://orcid.org/0000-0001-8409-3037; Thelen, Martin ORCID logoORCID: https://orcid.org/0000-0002-2785-9726; Reinke, Sarah ORCID logoORCID: https://orcid.org/0000-0001-9729-4030; Klapper, Wolfram; Gelebart, Pascal Francois ORCID logoORCID: https://orcid.org/0000-0003-2434-8987; Nicolai, Leo ORCID logoORCID: https://orcid.org/0000-0003-0776-5885; Marr, Carsten; Beltrán, Eduardo ORCID logoORCID: https://orcid.org/0000-0002-7266-4098; Megens, Remco T. A. ORCID logoORCID: https://orcid.org/0000-0001-9871-6696; Klein, Christoph; Baran-Marszak, Fanny; Rosenwald, Andreas; Bergwelt-Baildon, Michael von ORCID logoORCID: https://orcid.org/0000-0002-1952-052X; Bröckelmann, Paul J. ORCID logoORCID: https://orcid.org/0000-0001-9662-9900; Endres, Stefan ORCID logoORCID: https://orcid.org/0000-0002-4703-537X und Kobold, Sebastian ORCID logoORCID: https://orcid.org/0000-0002-5612-4673 (2025): Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma. In: Blood, Bd. 145, Nr. 14: S. 1536-1552 [PDF, 6MB]

Abstract

The success of targeted therapies for hematological malignancies has heralded their potential as both salvage treatment and early treatment lines, reducing the need for high-dose, intensive, and often toxic chemotherapeutic regimens. For young patients with classic Hodgkin lymphoma (cHL), immunotherapies provide the possibility to lessen long-term, treatment-related toxicities. However, suitable therapeutic targets are lacking. By integrating single-cell dissection of the tumor landscape and an in-depth, single-cell–based off-tumor antigen prediction, we identify CD86 as a promising therapeutic target in cHL. CD86 is highly expressed on Hodgkin and Reed-Sternberg cancer cells and cHL-specific tumor-associated macrophages. We reveal CD86–CTLA-4 as a key suppressive pathway in cHL, driving T-cell exhaustion. Cellular therapies targeting CD86 had extraordinary efficacy in vitro and in vivo and were safe in immunocompetent mouse models without compromising bacterial host defense in sepsis models. Our results prove the potential value of anti-CD86 immunotherapies for treating cHL.

Dokument bearbeiten Dokument bearbeiten